Welcome to our dedicated page for Celanese SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celanese's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celanese's regulatory disclosures and financial reporting.
Insider purchase disclosed: Celanese Corporation director Ganesh Moorthy bought 1,000 shares of CE common stock on 08/14/2025 at a reported price of $40.942 per share, increasing his direct holdings to 6,015 shares. The filing also shows an indirect holding of 3,000 shares held by the Ganesh and Hema Moorthy Revocable Living Trust. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Celanese Corp director Edward G. Galante reported an open-market purchase of 2,400 shares of Celanese common stock. The trade occurred on August 14, 2025 at a reported weighted average price of $41.272 per share, based on multiple transactions between $40.98 and $41.45.
After this purchase, Galante directly beneficially owned 21,377 Celanese shares, according to the filing.
Insider transaction reported by Celanese director Kim K.W. Rucker. The Form 4 records a derivative acquisition dated 08/11/2025: phantom stock units were recorded as acquired (transaction code A). The filing shows numeric values of 9,506.8 and a price figure of $47.42 in the derivative table. The form clarifies that each phantom share represents the right to receive one share of Celanese common stock and that these phantom shares reflect dividend equivalents credited under the company’s 2008 Deferred Compensation Plan.
The phantom shares become payable in common stock following the director’s termination of service, per the plan language included in the filing. The report was signed by an attorney-in-fact on 08/13/2025 and identifies Rucker as a director of Celanese (CE). The form does not provide additional context such as immediate share transfers, sales, or changes to direct holdings apart from the deferred compensation disclosure.
Deborah J. Kissire, a director of Celanese Corporation (CE), reported an acquisition of phantom stock on 08/11/2025 under the companys 2008 Deferred Compensation Plan. Each phantom share represents the right to receive one share of Celanese common stock. The filing lists 5,916.748 underlying shares and shows a referenced price of $47.42. The phantom shares represent dividend equivalents on compensation deferred under the Plan and become payable in common stock following the termination of Kissires service as a director.
The Form 4 was signed by an attorney-in-fact on 08/13/2025. The transaction is coded as an acquisition (A) of phantom stock rather than a sale or open-market trade, and the reporting person is identified as a director of the issuer.
Celanese Corporation director Jay V. Ihlenfeld reported an acquisition of phantom stock units tied to the company’s common shares. The Form 4 shows a transaction dated 08/11/2025 in which 10,227.219 units of phantom stock were acquired, with an associated figure of $47.42 shown in the table. Each phantom stock unit represents the right to receive one share of Celanese common stock.
These phantom units are described as dividend equivalents under the company’s 2008 Deferred Compensation Plan and are payable in shares of common stock as provided by the Plan following the termination of the reporting person’s service as a director. The filing identifies Ihlenfeld as a director and the Form is filed by one reporting person.
Kathryn Hill, a director of Celanese Corporation (CE), reported an acquisition of phantom stock units on 08/11/2025 on a Form 4 filing. The filing records the acquisition as dividend equivalents credited under the Company’s 2008 Deferred Compensation Plan; each phantom stock unit represents the right to receive one share of Celanese common stock and becomes payable in shares following termination of the director’s service.
The Form 4 shows a transaction entry of 1.86 (associated with the phantom stock), an indicated price of $47.42, and a post-transaction beneficial ownership figure of 2,946.61 derivative securities reported as held directly. The filing is signed by Christine Dryden as attorney-in-fact on 08/13/2025.
Celanese Corporation director Timothy Go was credited on 08/11/2025 with phantom stock units under the company’s 2008 Deferred Compensation Plan. Each phantom unit represents the right to receive one share of Celanese common stock, and the reported units are dividend equivalents that become payable in shares following the termination of the reporting person’s service. The Form 4 shows an allocation of 0.71 phantom shares at an indicated value of $47.42, bringing total reported phantom holdings to 1,114.71 units, reported as direct ownership. The entry is recorded in Table II as a derivative securities acquisition and reflects non-cash, deferred compensation rather than an open-market trade.
Edward G. Galante, a director of Celanese Corporation (CE), reported acquisition of phantom stock units on 08/11/2025 under the company’s 2008 Deferred Compensation Plan. The Form 4 records an acquisition (A) of phantom stock representing 6,797.555 underlying common shares at a reported per-unit value of $47.42, with the ownership form marked as Direct (D).
Each phantom share is described as the right to receive one share of common stock and represents dividend equivalents deferred under the Plan; those units become payable in shares following the termination of the reporting person’s service as a director. The Form 4 is signed by an attorney-in-fact for the reporting person.
Celanese Corporation entered into a five-year unsecured Revolving Credit Agreement providing a $1.75 billion facility with a $250 million sublimit for letters of credit, replacing its prior revolver. The facility is available in U.S. dollars and certain other currencies and is guaranteed by the company, Celanese US Holdings LLC and certain domestic subsidiaries.
Borrowings accrue interest based on Daily Simple SOFR, Term SOFR or a customary base rate plus a margin of 1.00%–2.00% (or 0.00%–1.00% for U.S. dollar base rate borrowings), with undrawn amounts subject to a commitment fee of 0.09%–0.35%, each range tied to the company’s senior unsecured debt ratings. The agreement includes customary covenants—maintenance of a leverage ratio and a fixed charge coverage ratio—limits on dividends until a target ratio is met, and customary default provisions. Separately, Celanese US agreed to a Sixth Amendment to its Term Loan Credit Agreement adding a minimum consolidated fixed charge coverage ratio and similar dividend limitations. Full terms are in Exhibits 10.1 and 10.2.
Celanese reported mixed second-quarter results. Net sales declined to $2,532 million from $2,651 million a year earlier, and six-month sales fell to $4,921 million from $5,262 million. Despite lower sales, net earnings attributable to Celanese were $199 million for the quarter versus $155 million in Q2 2024, with diluted EPS of $1.81 versus $1.41.
Cash and liquidity improved: cash and cash equivalents rose to $1,173 million and operating cash flow for the six months was $447 million. Long-term debt increased to $12,689 million (net of current installments) driven by new debt issuances in 2025, including the 2025 Offering. The Company completed tender offers to retire near-term notes and announced intent to divest the Micromax portfolio. Significant foreign currency translation losses and other comprehensive loss reduced AOCI to $(903) million, and accumulated goodwill impairment in Engineered Materials remains $1.5 billion.